GLYX-13 (Major Depressive Disorder) Market Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2023 Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. GLYX-13 is being developed by Naurex as an adjunctive therapy for MDD in patients with an inadequate response to antidepressants. The exact MOA of GLYX-13 is not fully understood, but it is hypothesized that it exerts its antidepressant effects by enhancing synaptic plasticity (Naurex, press release, December 12, 2013). GLYX-13 is being developed for IV administration and there is evidence to suggest that the NMDA receptor ligands can demonstrate rapid antidepressant effects (Popp et al., 2013). Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. For further information on this report, please visit http://www.radiantinsights.com/research/glyx-13-major-depressive-disorder-forecast-andmarket-analysis-to-2023 - Detailed information on GLYX-13 including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for GLYX-13 for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of GLYX-13 performance - Obtain sales forecast for GLYX-13 from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia). Table Of Content: 1 Table of Contents 5 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 9 2.3 Upcoming Related Reports 11 3 Disease Overview 12 3.1 Etiology and Pathophysiology 12 3.1.1 Etiology 12 3.1.2 Pathophysiology 12 3.2 Classification 14 3.3 Symptoms and Subtypes of Major Depressive Disorder 16 3.4 Prognosis 17 3.5 Quality of Life 17 Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare 4 Disease Management 18 4.1 Diagnosis and Treatment Overview 18 4.1.1 Diagnosis 18 4.1.2 Treatment Guidelines and Leading Prescribed Drugs 19 4.1.3 Clinical Practice 22 5 Competitive Assessment 27 5.1 Overview 27 6 Unmet Needs and Opportunities 29 6.1 Overview 29 6.2 More Effective Pharmacotherapies 30 6.2.1 Unmet Needs 30 6.2.2 Gap Analysis 31 6.2.3 Opportunities 32 6.3 More Favorable Side Effect Profiles 32 6.3.1 Unmet Needs 32
6.3.2 Gap Analysis 33 6.3.3 Opportunities 33 6.4 Rapid Onset of Antidepressant Effects 34 6.4.1 Unmet Needs 34 6.4.2 Gap Analysis 34 6.4.3 Opportunities 34 6.5 Personalized Treatment Approach 35 6.5.1 Unmet Needs 35 6.5.2 Gap Analysis 36 6.5.3 Opportunities 36 7 Pipeline Assessment 37 7.1 Overview 37 7.2 Promising Drugs in Clinical Development 37 8 GLYX-13 40 8.1 Overview 40 8.2 Efficacy 41 8.3 Safety 42 8.4 Dosing and Formulation 42 8.5 Potential Clinical and Commercial Positioning 43 8.6 SWOT Analysis 44 8.7 Forecast 44 To Get Sample Copy of Report visit @ http://www.radiantinsights.com/research/glyx-13major-depressive-disorder-forecast-and-market-analysis-to-2023#tabs-4 9 Appendix 46 9.1 Bibliography 46 9.2 Abbreviations 50 9.3 Methodology 53 9.4 Forecasting Methodology 53 9.4.1 Diagnosed MDD Patients 53 9.4.2 Percent of Drug-Treated Patients 53 9.4.3 General Pricing Assumptions 54 9.4.4 Generic Erosion 55 9.4.5 Pricing of Pipeline Agents 55 9.5 Physicians and Specialists Included in this Study 56 9.6 About the Authors 58 9.6.1 Analyst 58 9.6.2 Therapy Area Directors 58 9.6.3 Global Head of Healthcare 59 9.7 About GlobalData 60 9.8 Disclaimer 60
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com